Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1-2 Pilot Study of Rituximab (Rituxan) in Refractory Myasthenia Gravis.

NCT00619671 is registered in ClinicalTrials.gov with University of Vermont as lead sponsor.

NCT NCT00619671
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00619671 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1-2 Pilot Study of Rituximab (Rituxan) in Refractory Myasthenia Gravis.
Lead sponsor
University of Vermont
Phase
Phase 1/2
Overall status
Completed
Start date
April 30, 2004
Completion date
March 31, 2009
Enrollment
10 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

refractory myasthenia gravis